$BCTX
BriaCell Therapeutics Corp.

2023 Q4 Form 10-K Financial Statement

#000149315223038298 Filed on October 25, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3 2023
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.646M $2.538M $7.936M
YoY Change -23.38% 22.91% 9.19%
% of Gross Profit
Research & Development $6.857M $5.168M $15.34M
YoY Change 110.65% 63.07% 91.19%
% of Gross Profit
Depreciation & Amortization $3.820K $3.820K $15.27K
YoY Change 0.05% 0.0% -0.01%
% of Gross Profit
Operating Expenses $8.503M $7.706M $15.34M
YoY Change 57.37% 47.22% 91.19%
Operating Profit -$8.503M -$23.27M
YoY Change 57.37% 52.22%
Interest Expense $5.287M
YoY Change 9109.39%
% of Operating Profit
Other Income/Expense, Net $14.46M -$10.00 $2.970M
YoY Change 236.59% -100.0% -125.71%
Pretax Income $5.959M -$2.419M -$20.30M
YoY Change -638.51% 437.06% -24.35%
Income Tax
% Of Pretax Income
Net Earnings $6.002M -$2.419M -$20.30M
YoY Change -642.37% 437.06% -24.35%
Net Earnings / Revenue
Basic Earnings Per Share $0.38 -$1.30
Diluted Earnings Per Share -$0.50 -$0.15 -$1.30
COMMON SHARES
Basic Shares Outstanding 15.98M shares 15.62M shares
Diluted Shares Outstanding 16.67M shares 15.62M shares

Balance Sheet

Concept 2023 Q4 2023 Q3 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $13.65M $21.25M $21.25M
YoY Change -63.56% -48.22% -48.22%
Cash & Equivalents $13.65M $21.25M
Short-Term Investments
Other Short-Term Assets $4.741M $5.679M $5.679M
YoY Change 538.81% 343.31% 343.31%
Inventory
Prepaid Expenses $4.741M $5.679M
Receivables $21.41K $18.87K $18.87K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $18.41M $26.95M $26.95M
YoY Change -51.84% -36.36% -36.36%
LONG-TERM ASSETS
Property, Plant & Equipment $2.500K
YoY Change 0.0%
Goodwill
YoY Change
Intangibles $215.1K
YoY Change
Long-Term Investments $2.00 $2.00 $0.00
YoY Change 0.0% 0.0%
Other Assets
YoY Change
Total Long-Term Assets $211.3K $215.1K $215.1K
YoY Change -6.74% -6.63% -6.63%
TOTAL ASSETS
Total Short-Term Assets $18.41M $26.95M $26.95M
Total Long-Term Assets $211.3K $215.1K $215.1K
Total Assets $18.62M $27.16M $27.16M
YoY Change -51.58% -36.2% -36.2%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.047M $1.801M $1.801M
YoY Change 32.18% 288.85% 288.85%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.047M $1.801M $1.801M
YoY Change 7.44% 91.42% 91.42%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $15.06M $29.14M $29.14M
YoY Change -44.53% -6.92% -6.92%
Total Long-Term Liabilities $15.06M $29.14M $29.14M
YoY Change -44.53% -6.92% -6.92%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.047M $1.801M $1.801M
Total Long-Term Liabilities $15.06M $29.14M $29.14M
Total Liabilities $16.10M $30.94M $30.94M
YoY Change -42.73% -4.05% -4.05%
SHAREHOLDERS EQUITY
Retained Earnings -$74.65M -$80.65M
YoY Change 21.47% 33.64%
Common Stock $69.59M $69.59M
YoY Change -3.25% -1.73%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $2.721M -$3.777M -$3.777M
YoY Change
Total Liabilities & Shareholders Equity $18.62M $27.16M $27.16M
YoY Change -51.58% -36.2% -36.2%

Cashflow Statement

Concept 2023 Q4 2023 Q3 2023
OPERATING ACTIVITIES
Net Income $6.002M -$2.419M -$20.30M
YoY Change -642.37% 437.06% -24.35%
Depreciation, Depletion And Amortization $3.820K $3.820K $15.27K
YoY Change 0.05% 0.0% -0.01%
Cash From Operating Activities -$7.605M -$10.92M -$23.74M
YoY Change 114.69% 228.32% 90.2%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $4.000M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.000M $3.954M
YoY Change -2603.29% -205.65%
NET CHANGE
Cash From Operating Activities -$7.605M -10.92M -$23.74M
Cash From Investing Activities
Cash From Financing Activities 4.000M $3.954M
Net Change In Cash -$7.605M -6.919M -$19.79M
YoY Change 111.86% 98.51% 21.96%
FREE CASH FLOW
Cash From Operating Activities -$7.605M -$10.92M -$23.74M
Capital Expenditures
Free Cash Flow -$23.74M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001610820
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023 us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
CY2022 us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
CY2023Q3 BCTX Warrant Reserve
WarrantReserve
usd
CY2022Q3 BCTX Warrant Reserve
WarrantReserve
usd
CY2022 BCTX Adjustments To Additional Paid In Capital Expiration Of Options
AdjustmentsToAdditionalPaidInCapitalExpirationOfOptions
usd
CY2023 us-gaap Interest Expense
InterestExpense
usd
CY2023 BCTX Gain From Government Grant
GainFromGovernmentGrant
usd
CY2023 BCTX Repayment Government Grant
RepaymentGovernmentGrant
usd
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
usd
CY2023 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
usd
CY2023 us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
CY2022 us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
CY2023 us-gaap Income Tax Reconciliation Repatriation Of Foreign Earnings
IncomeTaxReconciliationRepatriationOfForeignEarnings
usd
CY2023 us-gaap Income Tax Reconciliation Equity In Earnings Losses Of Unconsolidated Subsidiary
IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary
usd
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2022Q3 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
usd
CY2022Q3 us-gaap Deferred Tax Liabilities Deferred Expense Deferred Financing Costs
DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts
usd
CY2023Q3 BCTX Valuation Allowance Change In Amount
ValuationAllowanceChangeInAmount
usd
CY2022Q3 BCTX Valuation Allowance Change In Amount
ValuationAllowanceChangeInAmount
usd
CY2023Q3 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
usd
CY2022Q3 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
usd
CY2023 us-gaap Interest Expense
InterestExpense
usd
CY2023 BCTX Gain On Government Grant
GainOnGovernmentGrant
usd
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-07-31
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--07-31
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
001-40101
CY2023 dei Entity Registrant Name
EntityRegistrantName
BRIACELL THERAPEUTICS CORP.
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-1099599
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
Suite 300 – 235 15th Street
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
West Vancouver
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
BC
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
V7T 2X1
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
V7T 2X1
CY2023 dei City Area Code
CityAreaCode
(604)
CY2023 dei Local Phone Number
LocalPhoneNumber
921-1810
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q1 dei Entity Public Float
EntityPublicFloat
105163751 usd
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
15981726 shares
CY2023 dei Auditor Firm
AuditorFirmId
1930
CY2023 dei Auditor Name
AuditorName
MNP LLP
CY2023 dei Auditor Location
AuditorLocation
Mississauga, Canada
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21251092 usd
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
41041652 usd
CY2023Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
18873 usd
CY2022Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
24103 usd
CY2023Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
5678542 usd
CY2022Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1280945 usd
CY2023Q3 us-gaap Assets Current
AssetsCurrent
26948507 usd
CY2022Q3 us-gaap Assets Current
AssetsCurrent
42346700 usd
CY2023Q3 us-gaap Equity Method Investments
EquityMethodInvestments
2 usd
CY2022Q3 us-gaap Equity Method Investments
EquityMethodInvestments
2 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
215068 usd
CY2022Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
230339 usd
CY2023Q3 us-gaap Assets Noncurrent
AssetsNoncurrent
215070 usd
CY2022Q3 us-gaap Assets Noncurrent
AssetsNoncurrent
230341 usd
CY2023Q3 us-gaap Assets
Assets
27163577 usd
CY2022Q3 us-gaap Assets
Assets
42577041 usd
CY2023Q3 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
1123739 usd
CY2022Q3 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
463280 usd
CY2023Q3 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
677718 usd
CY2022Q3 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
477807 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
1801457 usd
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
941087 usd
CY2023Q3 BCTX Warrant Liability Noncurrent
WarrantLiabilityNoncurrent
29139301 usd
CY2022Q3 BCTX Warrant Liability Noncurrent
WarrantLiabilityNoncurrent
31307022 usd
CY2023Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
29139301 usd
CY2022Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
31307022 usd
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
15981726 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15981726 shares
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
15518018 shares
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15518018 shares
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
69591784 usd
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
65589293 usd
CY2023Q3 BCTX Sharebased Payment Reserved
SharebasedPaymentReserved
7421950 usd
CY2022Q3 BCTX Sharebased Payment Reserved
SharebasedPaymentReserved
5228160 usd
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-138684 usd
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-138684 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-80652231 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-60349837 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-3777181 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
10328932 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
27163577 usd
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
42577041 usd
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15336638 usd
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8021489 usd
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7935626 usd
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7267452 usd
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-23272264 usd
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-15288941 usd
CY2023 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2969870 usd
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-11549962 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-20302394 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-26838903 usd
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.30
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.30
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.73
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.73
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15619676 shares
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15619676 shares
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15494091 shares
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15494091 shares
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
27671721 usd
CY2022 BCTX Stock Issued During Period Value Exercise Of Broker Warrants
StockIssuedDuringPeriodValueExerciseOfBrokerWarrants
2730754 usd
CY2022 BCTX Stock Issued During Period Value Exercise Of Private Placement Warrants
StockIssuedDuringPeriodValueExerciseOfPrivatePlacementWarrants
12162001 usd
CY2022 BCTX Stock Issued During Period Value Exercise Of Public Offering Warrants
StockIssuedDuringPeriodValueExerciseOfPublicOfferingWarrants
683905 usd
CY2022 BCTX Stock Issued During Period Value Shares Issuance Costs
StockIssuedDuringPeriodValueSharesIssuanceCosts
-57116 usd
CY2022 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
3074584 usd
CY2022 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
9098014 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-26838903 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
10328932 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
10328932 usd
CY2023 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2193790 usd
CY2023 BCTX Stock Issued During Period Value Exercise Of Warrants
StockIssuedDuringPeriodValueExerciseOfWarrants
2491 usd
CY2023 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
4000000 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-20302394 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-3777181 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-3777181 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-20302394 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-26838903 usd
CY2023 us-gaap Adjustment For Amortization
AdjustmentForAmortization
15271 usd
CY2022 us-gaap Adjustment For Amortization
AdjustmentForAmortization
15272 usd
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
2193790 usd
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
3074584 usd
CY2022 us-gaap Interest Expense
InterestExpense
979 usd
CY2022 BCTX Gain From Government Grant
GainFromGovernmentGrant
-3388 usd
CY2023 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-2119530 usd
CY2022 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
11658372 usd
CY2023 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-5230 usd
CY2022 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
11530 usd
CY2023 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
4397597 usd
CY2022 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
764054 usd
CY2023 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
660459 usd
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
249164 usd
CY2023 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
199911 usd
CY2022 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
135128 usd
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-23744860 usd
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12484376 usd
CY2023 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
1594 usd
CY2022 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
6509768 usd
CY2023 us-gaap Payments For Repurchase Of Equity
PaymentsForRepurchaseOfEquity
47294 usd
CY2022 us-gaap Payments For Repurchase Of Equity
PaymentsForRepurchaseOfEquity
10171732 usd
CY2022 BCTX Repayment Government Grant
RepaymentGovernmentGrant
23577 usd
CY2023 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4000000 usd
CY2022 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
57116 usd
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3954300 usd
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-3742657 usd
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-19790560 usd
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-16227033 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
41041652 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
57268685 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
21251092 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
41041652 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-80652231 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-60349837 usd
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-23744860 usd
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12484376 usd
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_848_eus-gaap--UseOfEstimates_zrHkbz6fJQth" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">  <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_865_z6xs0PO1toNg">Use of estimates, assumptions and judgements</span>:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The Company’s management believes that the estimates, judgment and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities at the dates of the consolidated financial statements, and the reported amount of expenses during the reporting periods. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Going Concern</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preparation of the consolidated financial statement on a going concern basis, which contemplates the realization of assets and payments of liabilities in the ordinary course of business. Should the Company be unable to continue as a going concern, it may be unable to realize the carrying value of its assets, including its intangible assets and to meet its liabilities as they become due.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Warrants and options</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company uses the Black-Scholes option-pricing model to estimate the fair value of options at the grant date, and the warrant liability at the grant date and each reporting period date. The key assumptions used in the model are the expected future volatility in the price of the Company’s shares and the expected life of the warrants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Income Taxes</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Provisions for taxes are made using the best estimate of the amount expected to be paid based on a qualitative assessment of all relevant factors. The Company reviews the adequacy of these provisions at the end of the reporting period. However, it is possible that at some future date an additional liability could result from audits by taxing authorities. Where the final outcome of these tax-related matters is different from the amounts that were initially recorded, such differences will affect the tax provisions in the period in which such determination is made.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible assets</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible assets are tested for impairment annually or more frequently if there is an indication of impairment. The carrying value of intangibles with definite lives is reviewed each reporting period to determine whether there is any indication of impairment. If there are indications of impairment the impairment analysis is completed and if the carrying amount of an asset exceeds its recoverable amount, the asset is impaired and impairment loss is recognized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p>
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2500 usd
CY2023Q3 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P20Y
CY2023 us-gaap Finite Lived Intangible Assets Amortization Method
FiniteLivedIntangibleAssetsAmortizationMethod
Straight-line
CY2023 BCTX Finite Lived Intangible Assets Inhouse Development Or Purchase
FiniteLivedIntangibleAssetsInhouseDevelopmentOrPurchase
Purchase
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
15271 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
15271 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
153984 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
215068 usd
CY2023Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 usd
CY2022Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 usd
CY2023Q3 us-gaap Finite Lived Patents Gross
FiniteLivedPatentsGross
305130 usd
CY2022Q3 us-gaap Finite Lived Patents Gross
FiniteLivedPatentsGross
305130 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
305130 usd
CY2022Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
305130 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
90062 usd
CY2022Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
74791 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
215068 usd
CY2022Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
230339 usd
CY2023 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
15271 usd
CY2022 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
15271 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
15271 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
15271 usd
CY2023Q3 BCTX Accrued Clinical Activities
AccruedClinicalActivities
20000 usd
CY2022Q3 BCTX Accrued Clinical Activities
AccruedClinicalActivities
69720 usd
CY2023Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
657718 usd
CY2022Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
408087 usd
CY2023Q3 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
677718 usd
CY2022Q3 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
477807 usd
CY2023Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
21251092 usd
CY2022Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
41041652 usd
CY2023Q3 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
29139301 usd
CY2022Q3 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
31307022 usd
CY2023Q3 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2022Q3 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2021Q1 us-gaap Share Price
SharePrice
3.40
CY2021Q2 us-gaap Share Price
SharePrice
3.92
CY2023Q3 us-gaap Share Price
SharePrice
6.69
CY2022Q3 us-gaap Share Price
SharePrice
6.50
CY2021Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
5.31
CY2021Q2 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
5.31
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
CY2021Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1 pure
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1 pure
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1 pure
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1 pure
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0088 pure
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0097 pure
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0451 pure
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0268 pure
CY2023Q3 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
2131400 shares
CY2023Q3 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
1585655 shares
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
2193790 usd
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
3074584 usd
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
2469999 usd
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-16555241 usd
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-17832395 usd
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-10283662 usd
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-20302394 usd
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-26838903 usd
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.27 pure
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.27 pure
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-20302394 usd
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-26838903 usd
CY2023 us-gaap Income Tax Reconciliation Nondeductible Expense Other
IncomeTaxReconciliationNondeductibleExpenseOther
-5481650 usd
CY2022 us-gaap Income Tax Reconciliation Nondeductible Expense Other
IncomeTaxReconciliationNondeductibleExpenseOther
-7246504 usd
CY2023 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
1068270 usd
CY2022 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
1591220 usd
CY2023 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
622220 usd
CY2022 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
828930 usd
CY2022 us-gaap Income Tax Reconciliation Repatriation Of Foreign Earnings
IncomeTaxReconciliationRepatriationOfForeignEarnings
7810 usd
CY2022 us-gaap Income Tax Reconciliation Equity In Earnings Losses Of Unconsolidated Subsidiary
IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary
-15420 usd
CY2023 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
3791160 usd
CY2022 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
4833964 usd
CY2023Q3 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
730 usd
CY2022Q3 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
730 usd
CY2023Q3 BCTX Deferred Tax Assets Marketable Securities
DeferredTaxAssetsMarketableSecurities
11760 usd
CY2022Q3 BCTX Deferred Tax Assets Marketable Securities
DeferredTaxAssetsMarketableSecurities
11760 usd
CY2023Q3 BCTX Deferred Tax Assets Warrant Liability
DeferredTaxAssetsWarrantLiability
3776710 usd
CY2022Q3 BCTX Deferred Tax Assets Warrant Liability
DeferredTaxAssetsWarrantLiability
4330580 usd
CY2023Q3 us-gaap Deferred Tax Assets Tax Deferred Expense
DeferredTaxAssetsTaxDeferredExpense
734300 usd
CY2022Q3 us-gaap Deferred Tax Assets Tax Deferred Expense
DeferredTaxAssetsTaxDeferredExpense
1105220 usd
CY2023Q3 us-gaap Deferred Tax Assets Other Loss Carryforwards
DeferredTaxAssetsOtherLossCarryforwards
3842320 usd
CY2022Q3 us-gaap Deferred Tax Assets Other Loss Carryforwards
DeferredTaxAssetsOtherLossCarryforwards
2714150 usd
CY2023Q3 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
4913950 usd
CY2022Q3 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
4015960 usd
CY2023Q3 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
2685825 usd
CY2023Q3 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
15965594 usd
CY2022Q3 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
12178400 usd
CY2023Q3 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
15920430 usd
CY2022Q3 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
12130030 usd
CY2023Q3 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
45160 usd
CY2022Q3 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
48370 usd
CY2023Q3 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
45160 usd
CY2022Q3 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
48370 usd
CY2023Q3 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
45160 usd
CY2022Q3 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
48370 usd
CY2023 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
2790400 usd
CY2023Q3 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
23340000 usd
CY2023 BCTX Operating Loss Carryforward Expiration Date Description
OperatingLossCarryforwardExpirationDateDescription
The federal net operating losses have expiry periods ranging between 2033 and indefinitely
CY2023Q3 us-gaap Deferred Tax Assets Operating Loss Carryforwards Foreign
DeferredTaxAssetsOperatingLossCarryforwardsForeign
14231000 usd
CY2023 BCTX Foreign Operating Loss Carryforward Expiration Date Description
ForeignOperatingLossCarryforwardExpirationDateDescription
The Canadian net operating losses have expiry periods ranging between 2035 and 2043.
CY2023 us-gaap Investment Income Interest
InvestmentIncomeInterest
891213 usd
CY2022 us-gaap Investment Income Interest
InvestmentIncomeInterest
136731 usd
CY2022 us-gaap Interest Expense
InterestExpense
979 usd
CY2023 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-2119530 usd
CY2022 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
11658372 usd
CY2022 BCTX Gain On Government Grant
GainOnGovernmentGrant
3388 usd
CY2023 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-40873 usd
CY2022 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-30730 usd
CY2023 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2969870 usd
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-11549962 usd
CY2023 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-20302394 usd
CY2022 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-26838903 usd
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15619676 shares
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15619676 shares
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15494091 shares
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15494091 shares
CY2023Q3 us-gaap Noncurrent Assets
NoncurrentAssets
215068 usd
CY2022Q3 us-gaap Noncurrent Assets
NoncurrentAssets
230339 usd

Files In Submission

Name View Source Status
0001493152-23-038298-index-headers.html Edgar Link pending
0001493152-23-038298-index.html Edgar Link pending
0001493152-23-038298.txt Edgar Link pending
0001493152-23-038298-xbrl.zip Edgar Link pending
aud_001.jpg Edgar Link pending
bctx-20230731_cal.xml Edgar Link unprocessable
bctx-20230731.xsd Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
ex4-1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-k.htm Edgar Link pending
form10-k_0001.jpg Edgar Link pending
form10-k_001.jpg Edgar Link pending
form10-k_002.jpg Edgar Link pending
form10-k_003.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
bctx-20230731_lab.xml Edgar Link unprocessable
bctx-20230731_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
form10-k_htm.xml Edgar Link completed
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
bctx-20230731_def.xml Edgar Link unprocessable